Healthcare Industry News: RT Technology
News Release - May 15, 2006
New Study Reports on Improved Disease Detection with the ThinPrep(R) Imaging System
MARLBOROUGH, Mass.--(HSMN NewsFeed)--May 15, 2006--Cytyc Corporation (Nasdaq: CYTC ), a leading women's health company, today announced that a study published in the May-June issue of Acta Cytologica reports that implementation of the ThinPrep® Imaging System significantly increased detection of cervical squamous intraepithelial lesions compared to manually screened ThinPrep® Pap Tests. Acta Cytologica is the official periodical of the International Academy of Cytology."The results of this study continue to demonstrate the clinical effectiveness of our state-of-the-aRT Technology," said Ellen Sheets, M.D., Cytyc's chief medical officer. "We believe the ThinPrep Imaging System provides laboratories, clinicians, and patients the best technology available for cervical cancer screening."
Cytyc Corporation is a leading women's health company that designs, develops, manufactures, and markets innovative and clinically effective products for cervical cancer screening, breast cancer risk assessment, treatment of excessive menstrual bleeding, and treatment of breast cancer.
Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC. Cytyc and ThinPrep are registered trademarks of Cytyc Corporation.
Forward-looking statements in this press release are made pursuant to the provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements relating to Cytyc's future financial condition, operating results and economic performance, and management's expectations regarding key customer relationships, future growth opportunities, product acceptance and business strategy, constitute forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from those statements. Risks and uncertainties include, among others, dependence on key personnel and customers as well as reliance on proprietary technology, uncertainty of product development efforts and product acceptance, management of growth and product diversification, entry into new market segments domestically and new markets internationally, risks associated with litigation, the effective integration of acquired businesses and technologies, competition and competitive pricing pressures, risks associated with the FDA regulatory approval processes and healthcare reimbursement policies in the United States and abroad, introduction of technologies that are disruptive to Cytyc's business and operations, the impact of new accounting requirements and governmental rules and regulations, as well as other risks detailed in Cytyc's filings with the Securities and Exchange Commission, including those under the heading "Risk Factors" in its 2005 Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q filed with the Commission. Cytyc cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Cytyc disclaims any obligation to publicly update or revise any such statements to reflect any change in its expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Source: Cytyc
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
